-$0.67 Earnings Per Share Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter

Equities research analysts forecast that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will post earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.73). Zynerba Pharmaceuticals posted earnings per share of ($0.60) in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.7%. The business is scheduled to issue its next earnings results on Monday, March 11th.

On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($2.94) to ($2.79). For the next financial year, analysts anticipate that the firm will report earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.23.

A number of research analysts have recently weighed in on ZYNE shares. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Saturday, November 17th. HC Wainwright set a $23.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 13th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Tuesday, October 2nd. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $17.75.

Shares of ZYNE opened at $4.82 on Monday. Zynerba Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $15.14. The company has a market cap of $84.96 million, a PE ratio of -1.94 and a beta of 4.49.

Hedge funds have recently added to or reduced their stakes in the business. Thompson Siegel & Walmsley LLC purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $157,000. Raymond James & Associates purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter worth approximately $164,000. GSA Capital Partners LLP purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $177,000. Zeke Capital Advisors LLC purchased a new stake in Zynerba Pharmaceuticals in the 3rd quarter worth approximately $193,000. Finally, Engineers Gate Manager LP purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter worth approximately $231,000. 15.24% of the stock is owned by hedge funds and other institutional investors.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

See Also: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply